Skip Navigation LinksHome > June 2014 - Volume 9 - Issue 6 > Defining Subgroups of Small-Cell Lung Cancer
Journal of Thoracic Oncology:
doi: 10.1097/JTO.0000000000000176

Defining Subgroups of Small-Cell Lung Cancer

Dowlati, Afshin MD; Wildey, Gary PhD

Free Access
Article Outline
Collapse Box

Author Information

Division of Hematology and Oncology, Case Western Reserve University and University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center, Cleveland, Ohio.

Disclosure: The authors declare no conflict of interest.

Address for correspondence: Afshin Dowlati, MD, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106. E-mail:

Small-cell lung cancer (SCLC) is a disease for which there has been no advance in systemic therapy for the past 30 years. In the background of this sobering data are many attempts to find targeted therapy that can have a real impact on patient outcome.1 These attempts may have failed largely because of our inability to identify subgroups of SCLC patients who have an appropriate predictive biomarker for response. Thus, in this setting, investigators are attempting to define, similar to non–small-cell lung cancer (NSCLC), subgroups of SCLC which behave differently. This represents a departure from what has traditionally been viewed as a homogeneous disease. An obvious subgroup, representing approximately 1% of all SCLC, are patients with so-called “peripheral SCLC” which present with a solitary pulmonary nodule and whom are candidates for surgery.2 Most genomic data published to date have focused on this group,3,4 which has a very different clinical course than the classic SCLC we observe in everyday clinical practice. Another subgroup is the so-called “combined SCLC,” previously called “mixed SCLC,” which has histological features of both SCLC and NSCLC and may also behave differently.5 This entity represents a fascinating disease because it puts into question the cellular origin of SCLC, which is an area of active investigation.6,7

With this knowledge, Varghese et al. are identifying yet another rare subgroup, SCLC patients who have never smoked. In our clinical practice, we have only seen three never-smoker patients with SCLC, and without epidermal growth factor receptor (EGFR) mutations, among 420 patients (0.7%) who are part of our ongoing clinicopathological SCLC database. Interest in this subgroup has mainly arisen from the observations that EGFR-mutant NSCLC patients treated with EGFR kinase inhibitors may transform into SCLC as a mechanism of resistance.8 Because we are now routinely performing repeat biopsies on patients with EGFR mutation disease, this transformation is being seen on a much more common basis (3 patients in the past 4 months in our clinical practice alone). These patients seem to be somewhat more resistant to SCLC-directed therapy with initial impressions of lower response rates and shorter time to progression.

Multiple explanations for the occurrence of SCLC in never-smokers may be evoked. One explanation may simply be that it represents “an extrapulmonary SCLC,” which may occur in people who have never smoked and can arise in various organs, including the gastrointestinal and genitourinary systems, but just happens to occur in the lung.9 The causative factor for extrapulmonary SCLC remains unknown. Another putative explanation may be that SCLC of never-smokers may simply represent a dedifferentiation of a previously well-differentiated cancer, similar to what may be seen in prostate cancer transformation into small-cell variety after prolonged androgen ablation.10 Indeed, we observed a case of NSCLC transforming into SCLC without EGFR tyrosine kinase inhibitor therapy. Another plausible explanation may be that we are really dealing with a “combined SCLC,” but because of a paucity of biopsy material, only the SCLC part is being seen.5 Yet another explanation is that the observed SCLC in the chest of a never-smoker may be a so-called “Askin tumor,” a primitive neuroectodermal tumor of the Ewing family tumors. Although these are generally seen in children, adults can also be afflicted.11 These rare, small, blue cell tumors can be diagnosed as SCLC in the adult population. We have recently seen a case in a 70-year-old light-smoker female who presented with SCLC. After sequencing the tumor, we discovered the classic fusion oncogene for Ewing’s sarcoma, translocation of the Ewing sarcoma (EWS) gene on chromosome 22 to the Fli-1 proto-oncogene (FLI1) gene on chromosome 11, indicating most likely a tumor from the Ewing family. It is unclear whether this translocation was part of the mutation panel used in the study by Varghese et al. Finally, a simple explanation may be related to the use of self-administered smoking history questionnaires, which have always been criticized.

The study by Varghese et al. also highlights the difficulties in obtaining tissue from SCLC patients for genomic analyses. Indeed, in their series, only two patients had enough tissue for targeted next-generation sequencing. The group at Memorial Sloan Kettering Cancer Center should be commended for their persistent efforts to further define and understand a disease for which therapeutic progress is long overdue.

Back to Top | Article Outline


1. Nickolich M, Babakoohi S, Fu P, Dowlati A. Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution. Clin Lung Cancer. 2014;15:207–212

2. Lim E, Belcher E, Yap YK, Nicholson AG, Goldstraw P. The role of surgery in the treatment of limited disease small cell lung cancer: time to reevaluate. J Thorac Oncol. 2008;3:1267–1271

3. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44:1111–1116

4. Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104–1110

5. Babakoohi S, Fu P, Yang M, Linden PA, Dowlati A. Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer. 2013;14:113–119

6. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell. 2011;19:754–764

7. Song H, Yao E, Lin C, Gacayan R, Chen MH, Chuang PT. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc Natl Acad Sci U S A. 2012;109:17531–17536

8. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–2247

9. Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 2009;35:228–236

10. Tan HL, Sood A, Rahimi HA, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2013;20:890–903

11. Imamura F, Funakoshi T, Nakamura S, Mano M, Kodama K, Horai T. Primary primitive neuroectodermal tumor of the lung: report of two cases. Lung Cancer. 2000;27:55–60

Copyright © 2014 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer.


Article Tools


Other Ways to Connect



Visit on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.